NCT00292760View on ClinicalTrials.gov

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Chronic Lymphocytic Leukaemia

Interventions

DRUG

Alemtuzumab

DRUG

Methyprednisolone

All Listed Sponsors

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT00292760 - A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion | Biotech Hunter | Biotech Hunter